Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy

Shun Lu, Nicolas Girard, James Chih-Hsin Yang, Frances A. Shepherd, Xiaorong Dong, Surein Arulananda, Giulio Metro, Hidetoshi Hayashi, Laura Bonanno, Yu Jung Kim, Zhe Liu, Myung-Ju Ahn, Yuping Sun, Thuong Vu Le, Silvia Novello, Sang-We Kim, Yanqiu Zhao, Phuong Nguyen, Mariana Brandão, Yongsheng Wang, Missak Haigentz, Daniel Misch, Mariano Provencio Pulla, Wen-Tsung Huang, Clarissa Baldotto, Marcelo Tatangelo, Colin R. Lindsay, Ryan J. Hartmaier, Rafal Lolo, Balakumar Swaminathan, Alexander Gont, Francis Maria Esposito, Yusuke Okuma

Open source

DOI: 10.1056/nejmoa2611335
Published: 2026-10-25
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2611335,
  title = {Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy},
  author = {Shun Lu and Nicolas Girard and James Chih-Hsin Yang and Frances A. Shepherd and Xiaorong Dong and Surein Arulananda and Giulio Metro and Hidetoshi Hayashi and Laura Bonanno and Yu Jung Kim and Zhe Liu and Myung-Ju Ahn and Yuping Sun and Thuong Vu Le and Silvia Novello and Sang-We Kim and Yanqiu Zhao and Phuong Nguyen and Mariana Brandão and Yongsheng Wang and Missak Haigentz and Daniel Misch and Mariano Provencio Pulla and Wen-Tsung Huang and Clarissa Baldotto and Marcelo Tatangelo and Colin R. Lindsay and Ryan J. Hartmaier and Rafal Lolo and Balakumar Swaminathan and Alexander Gont and Francis Maria Esposito and Yusuke Okuma},
  year = {2026},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa2611335},
  url = {https://doi.org/10.1056/nejmoa2611335}
}

RIS

TY  - JOUR
TI  - Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
AU  - Shun Lu
AU  - Nicolas Girard
AU  - James Chih-Hsin Yang
AU  - Frances A. Shepherd
AU  - Xiaorong Dong
AU  - Surein Arulananda
AU  - Giulio Metro
AU  - Hidetoshi Hayashi
AU  - Laura Bonanno
AU  - Yu Jung Kim
AU  - Zhe Liu
AU  - Myung-Ju Ahn
AU  - Yuping Sun
AU  - Thuong Vu Le
AU  - Silvia Novello
AU  - Sang-We Kim
AU  - Yanqiu Zhao
AU  - Phuong Nguyen
AU  - Mariana Brandão
AU  - Yongsheng Wang
AU  - Missak Haigentz
AU  - Daniel Misch
AU  - Mariano Provencio Pulla
AU  - Wen-Tsung Huang
AU  - Clarissa Baldotto
AU  - Marcelo Tatangelo
AU  - Colin R. Lindsay
AU  - Ryan J. Hartmaier
AU  - Rafal Lolo
AU  - Balakumar Swaminathan
AU  - Alexander Gont
AU  - Francis Maria Esposito
AU  - Yusuke Okuma
PY  - 2026
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2611335
UR  - https://doi.org/10.1056/nejmoa2611335
ER  -

APA

Lu, S., Girard, N., Yang, J. C., Shepherd, F. A., Dong, X., Arulananda, S., Metro, G., Hayashi, H., Bonanno, L., Kim, Y. J., Liu, Z., Ahn, M., Sun, Y., Le, T. V., Novello, S., Kim, S., Zhao, Y., Nguyen, P., Brandão, M., Wang, Y., Haigentz, M., Misch, D., Pulla, M. P., Huang, W., Baldotto, C., Tatangelo, M., Lindsay, C. R., Hartmaier, R. J., Lolo, R., Swaminathan, B., Gont, A., Esposito, F. M., & Okuma, Y. (2026). Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2611335

Source records

crossref · retrieved 2026-11-07T14:01:24.126Z